Clinical trials: bipolar
Bipolar Disorder, Substance Dependence
Modifying Group Therapy for Bipolar Substance Abusers - 1
The purpose of this study is to modify Integrated Group Therapy (IGT), which is has been found successful for patients with bipolar disorder (BD) and substance use disorder(SUD), so that it can be more readily adopted by…
- Trial name
- NCT00227838
- Testing
- Behavior Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Bipolar I Disorder
Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative
Bipolar disorder (BD), especially BD type I, is a highly prevalent mental disorder and a is a highly prevalent mental disorder and an important factor for suicide.
- Trial name
- R-LiNK (NCT04209140)
- Testing
- lithium treatment
- Where
- France
- Volunteers
- 320 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Bipolar Disorder, Schizophrenia
Connectomics in Psychiatric Classification of Bipolar Disorder and Schizophrenia
Washington University Early Recognition Center is conducting a research study to examine brain functional connectivity and network patterns in participants with bipolar disorder and schizophrenia.
- Trial name
- NCT02756065
- Testing
- no intervention
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Washington University Early Recognition Center
Depressive Disorder, Bipolar Disorder
Early Integrated Intervention in Severe Affective Disorders
The purpose of this study is to determine whether early integrated prophylactic combined medical and psychological outpatient treatment is associated with a better prognosis in patients with severe unipolar and bipolar affective…
- Trial name
- NCT00253071
- Testing
- Prophylactic combined medical and psychological treatment
- Where
- Denmark
- Volunteers
- 426 people
- Sponsor
- Hovedstadens Sygehusfaelesskab
Epilepsy
WEUSKOP6166: Lamotrigine and Aseptic Meningitis
The objective of the study is to quantify the number of cases of aseptic meningitis among users of Lamotrigine. This study is a cross-sectional study design using data on lamotrigine patients within the Thomson Reuters…
- Trial name
- NCT01657864
- Testing
- Lamotrigine
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Bipolar, Mania, Bipolar, Mixed State
Prazosin as an Antimanic Agent in Severe Mania or Mixed States
Mania has been considered to be, in part, a hyperadrenergic state. One focus of treatment of mania involves directly targeting this hyperexcitable state by reducing arousal with antiadrenergic agents.
- Trial name
- NCT01621165
- Testing
- Addition of prazosin to usual care (add-on study)
- Sponsor
- Mclean Hospital
Bipolar I
Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
This will be an open-label uncontrolled trial to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to patients with bipolar I disorder.
- Trial name
- ATLAS (NCT01710709)
- Testing
- Aripiprazole
- Where
- 142 sites in United States, Canada and 8 more
- Volunteers
- 748 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar II Disorder, Depression, Bipolar
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD…
- Conditions
- Bipolar II Disorder, Depression, Bipolar, Suicidality
- Trial name
- NCT06706232
- Testing
- Psilocybin, Therapeutic Support
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bipolar Disorder, Bipolar Depression
PET and MRI Brain Imaging of Bipolar Disorder
The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2.
- Conditions
- Bipolar Disorder, Bipolar Depression, Unipolar Depression
- Trial name
- NCT01880957
- Testing
- Lithium, Lamotrigine
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Bipolar Disorder Type 1
Use of Ketosis in Modulating Metabolic Pathways in Bipolar Disorder
The goal of this clinical trial is to test how specific components of diet affect brain function and behavior for individuals with bipolar.
- Trial name
- NCT06373016
- Testing
- Glucose, Ketones
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Adolescent, Bipolar Depression
HD-tDCS for Adolescent Bipolar Depression Targeting S1
This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression.
- Conditions
- Adolescent, Bipolar Depression, tDCS, Primary Somatosensory Cortex
- Trial name
- NCT07246044
- Testing
- Active HD-tDCS, Antipsychotics, mood stabilizers, etc.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study
The study aims to evaluate whether or not an EEG (a type of brain scan) is useful in diagnosing youth with either ADHD, BPD, ASD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder
- Trial name
- NCT01506232
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depression
Brain Network Activation Analysis to Diagnose/Assess Treatment of Unipolar Major Depression and Bipolar I Depression
The investigators are conducting this study to test the usefulness of a new type of analysis of electroencephalographic (EEG) recordings called brain network activation or BNA.
- Trial name
- BNA-Mood (NCT01683214)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Bipolar Depression
The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder
The primary objective of this 15-week clinical trial is to test the hypothesis that treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA), has significantly greater efficacy than…
- Trial name
- NCT00719706
- Testing
- acetyl-l-carnitine PLUS alpha-lipoic acide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mclean Hospital
Acne, Scar
Comparison of Efficacy Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency for Acne Scar
Compare the efficacy and safety profile of microneedling radiofrequency and that of bipolar radiofrequency treatment for acne scar.
- Trial name
- NCT02207738
- Testing
- microneedling radiofrequency device, bipolar radiofrequency
- Where
- South Korea
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Bipolar Disorder
3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159744
- Testing
- Asenapine, Olanzapine
- Volunteers
- 488 people
- Sponsor
- Organon and Co
Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality…
- Conditions
- Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression, Major Depressive Disorder (MDD)
- Trial name
- KET-DBT (NCT07569198)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Joshua Rosenblat
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.